Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies

Elisabeth A. Lambert, Carolina I. Sari, Nina Eikelis, Sarah E. Phillips, Mariee Grima, Nora E. Straznicky, John B. Dixon, Murray Esler, Markus P. Schlaich, Geoffrey A. Head, Gavin W. Lambert

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    Objective: Because sympathetic nervous system activity plays a detrimental role in metabolic and cardiovascular health, this study compared the effects of a centrally acting sympatholytic agent, the effects of a weight loss (WL) program using a low-calorie diet, and the effects of a combination of both. Methods: Young (18-30 years) male subjects with overweight (BMI > 25 kg/m2) were allocated to a WL program (n = 10), a moxonidine treatment course (M; n = 10, 0.4 mg/d), a combination of both (WL + M; n = 11), or to a control (C) group (n = 6) for 6 months. Muscle sympathetic nerve activity (MSNA), endothelial function, renal function (Cockcroft-Gault formula), and the metabolic profile were assessed before and after intervention. Results: WL occurred in the WL and WL + M groups (−7.6 ± 1.9 kg, P < 0.001 in both). MSNA and systolic blood pressure decreased similarly in the WL, M, and WL + M groups (by ∼10 bursts/min, P < 0.001, and by ∼9 mm Hg, P < 0.05). All other parameters for the WL, C, and M groups remained unchanged. In the WL + M group, decreased total cholesterol (−0.78 ± 0.23 mmol/L, P < 0.001), decreased low-density lipoprotein cholesterol (−0.49 ± 0.16 mmol/L, P < 0.01), decreased insulin (−6.5 ± 2.8 mmol/L, P < 0.05), and attenuated glomerular hyperfiltration (−19 ± 5 mL/min, P < 0.01) occurred. Conclusions: The combination of moxonidine with a WL program has beneficial effects on aspects of the metabolic profile and end organ damage in young males with overweight.

    Original languageEnglish
    Pages (from-to)1894-1902
    Number of pages9
    JournalObesity
    Volume25
    Issue number11
    DOIs
    Publication statusPublished - 1 Nov 2017

      Fingerprint

    Cite this

    Lambert, E. A., Sari, C. I., Eikelis, N., Phillips, S. E., Grima, M., Straznicky, N. E., ... Lambert, G. W. (2017). Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies. Obesity, 25(11), 1894-1902. https://doi.org/10.1002/oby.21962